Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04728061




Registration number
NCT04728061
Ethics application status
Date submitted
22/01/2021
Date registered
28/01/2021
Date last updated
2/12/2021

Titles & IDs
Public title
Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of GEn1E-1124
Scientific title
A Phase 1a/1b, Randomized, Double-blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of GEn1E-1124 After Single and Multiple IV Infusion Dosing in Healthy Volunteers
Secondary ID [1] 0 0
GEn1E-1124-001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Healthy 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Gen1E-1124
Treatment: Drugs - Placebo

Experimental: Single Ascending Dose -

Experimental: Multiple Ascending Dose -


Treatment: Drugs: Gen1E-1124
Intravenously-infused Gen1E-1124 in vehicle.

Treatment: Drugs: Placebo
Intravenously-infused vehicle.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
The incidence of adverse events from the start of randomization through the final follow-up visit
Timepoint [1] 0 0
Up to 14 days post-dose
Secondary outcome [1] 0 0
Plasma levels of GEn1E-1124 and potential metabolites
Timepoint [1] 0 0
Through 24 hours post-dose
Secondary outcome [2] 0 0
Urine levels of GEn1E-1124 and potential metabolites
Timepoint [2] 0 0
Through 24 hours post-dose
Secondary outcome [3] 0 0
Cytokines measured in whole blood
Timepoint [3] 0 0
Up to 24 hours post-dose
Secondary outcome [4] 0 0
Selected biomarkers measured in whole blood
Timepoint [4] 0 0
Up to 24 hours post-dose

Eligibility
Key inclusion criteria
1. Healthy male and female subjects;

2. Between 18 and 55 years of age;

3. Provide a signed EC-approved consent form;

4. Generally healthy, in the opinion of the Investigator;

5. Body Mass Index (BMI) 18 to 30 kg/m^2;

6. Creatinine clearance with in specific parameter;

7. Using method of contraception;

8. Willing and able to comply with protocol requirements for the duration of the study.
Minimum age
18 Years
Maximum age
55 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
1. Subjects taking prohibited medication;

2. Subjects with a history or presence of clinically significant medical or psychiatric
disease;

3. Subjects who have regularly used nicotine-containing products ;

4. Subjects who have used caffeine-containing products;

5. Subjects who are unable to comply with eating a standardized meal during the study;

6. Subjects with a hospital admission or major surgery within 30 days prior to Screening;

7. Subjects with a plasma donation within 7 days prior to Screening;

8. Subjects who have not abstained from alcoholic beverages/alcohol-containing products
at least 72 hours prior to first dose, or plan to consume them at any time through
completion of the Follow-up Visit;

9. Subjects who cannot refrain from strenuous exercise from 72 hours prior to dose
administration through completion of the Follow-up Visit;

10. Subjects who are pregnant or breastfeeding

11. Subjects who have participated (taken investigative drug and/or device) in another
clinical trial within 90 days prior to Screening;

12. Subjects who are employees of the study unit or their family members, students who are
working in the study unit, or family members of the Investigator or Sponsor.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Other
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
7/01/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
18/06/2021
Sample size
Target
Accrual to date
Final
48
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
New Zealand
State/province [1] 0 0
Christchurch

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
GEn1E Lifesciences
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
In this early phase clinical research study, the investigational drug will be administered to
64 healthy volunteers in a double-blind, placebo-controlled manner, at a one research center.
The objectives of the study are to assess what the body does to the investigational drug,
what the investigational drug does to the body and also to observe the safety and
tolerability of the investigational drug healthy volunteers.
Trial website
https://clinicaltrials.gov/ct2/show/NCT04728061
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Ritu Lal, PhD, MS
Address 0 0
GEn1E Lifesciences
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT04728061